Massimo has Haemophilia A


Our ambition

Our ambition is to change possibilities for people with haemophilia. Every step of our journey is focused on improving treatment options, providing better access to care and following through on our commitment to understand the needs of people with haemophilia.

Our partnering focus

We seek partners and opportunities within treatment, prevention, and detection of bleeding in people with haemophilia:

  • Improvement of FVIII and FIX based replacement therapies for people with haemophilia A or B, including protraction technologies for long-acting prophylaxis and less immunogenic products
  • Improvement of bypassing therapies for on demand as well as prophylactic therapy in people with haemophilia
  • Detection, prevention, and treatment of haemophilic arthropathy
  • Improved technologies, e.g. for expression, formulation and delivery of biopharmaceuticals for haemophilia
  • Identification of novel treatment concepts including non-replacement therapies that improve haemostasis in people with haemophilia

Contact us

For further information, please contact Jørn Müller 


Download partnering for innovation brochure


Where to meet us

We are attending events all over the world to meet with new potential partners.

Event calendar


R&D pipeline

Read more about our haemophilia pipeline.